Literature DB >> 20565462

Increasing the dose of voriconazole compensates for enzyme induction by phenytoin.

Isabel Spriet, Philippe Meersseman, Wouter Meersseman, Jan de Hoon, Ludo Willems.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2010        PMID： 20565462      PMCID： PMC2883763          DOI： 10.1111/j.1365-2125.2010.03650.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN： 0306-5251            Impact factor:   4.335


× No keyword cloud information.
  6 in total

Review 1.  Factors influencing the magnitude and clinical significance of drug interactions between azole antifungals and select immunosuppressants.

Authors:  Aline H Saad; Daryl D DePestel; Peggy L Carver
Journal:  Pharmacotherapy       Date:  2006-12       Impact factor: 4.705

Review 2.  Antifungal therapeutic drug monitoring: established and emerging indications.

Authors:  David Andes; Andres Pascual; Oscar Marchetti
Journal:  Antimicrob Agents Chemother       Date:  2008-10-27       Impact factor: 5.191

3.  Phenytoin-induced reduction of voriconazole serum concentration is not compensated by doubling the dosage.

Authors:  Jan-Willem C Alffenaar; Kim C M van der Elst; Donald R A Uges; Jos G W Kosterink; Simon M G J Daenen
Journal:  Br J Clin Pharmacol       Date:  2009-09       Impact factor: 4.335

4.  Pharmacokinetics, metabolism and bioavailability of the triazole antifungal agent voriconazole in relation to CYP2C19 genotype.

Authors:  Ina Scholz; Heike Oberwittler; Klaus-Dieter Riedel; Jürgen Burhenne; Johanna Weiss; Walter E Haefeli; Gerd Mikus
Journal:  Br J Clin Pharmacol       Date:  2009-12       Impact factor: 4.335

Review 5.  Clinical relevance of the pharmacokinetic interactions of azole antifungal drugs with other coadministered agents.

Authors:  Roger J M Brüggemann; Jan-Willem C Alffenaar; Nicole M A Blijlevens; Eliane M Billaud; Jos G W Kosterink; Paul E Verweij; David M Burger
Journal:  Clin Infect Dis       Date:  2009-05-15       Impact factor: 9.079

6.  Coadministration of voriconazole and phenytoin: pharmacokinetic interaction, safety, and toleration.

Authors:  Lynn Purkins; Nolan Wood; Parviz Ghahramani; Edward R Love; Malcolm D Eve; Anitra Fielding
Journal:  Br J Clin Pharmacol       Date:  2003-12       Impact factor: 4.335
  6 in total
  2 in total

1.  Determination of a suitable voriconazole pharmacokinetic model for personalised dosing.

Authors:  David A J McDougall; Jennifer Martin; E Geoffrey Playford; Bruce Green
Journal:  J Pharmacokinet Pharmacodyn       Date:  2015-12-16       Impact factor: 2.745

2.  Application of modified Michaelis - Menten equations for determination of enzyme inducing and inhibiting drugs.

Authors:  Saganuwan Alhaji Saganuwan
Journal:  BMC Pharmacol Toxicol       Date:  2021-10-11       Impact factor: 2.483
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.